(2S)-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid

We are (2S)-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid CAS:15401-08-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: (2S)-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid
CAS.NO: 15401-08-8
Molecular Formula:C15H24N2O5
Molecular Weight:312.36100

Synonyms:
Boc-L-Pro-Pro-OH
Boc-Pro-Pro-OH
Boc-Pro-Pro-COOH
N-tert-butoxycarbonyl-prolyl-proline
N-tert-butoxycarbonyl-L-prolyl-L-proline
(S)-1-((S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxylic acid

Physical and Chemical Properties:
Density: /
Boiling point: /
Melting point : 185-187 ºC (ethyl acetate hexane )
Flash point: /
Refractive index: /

Specification:
Appearance: White Crystalline Powder
Purity:≥98%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -20ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

(2S)-1-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid


Related News: The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.ethyl 5-(ethoxycarbonylsulfamoyl)-1-methylpyrazole-4-carboxylate ut others aren’t convinced — they think one of the country’s most influential state media outlets could be promoting pseudoscience and false hope.2-cloro-N- (2,6-dietilfenil) acetamida CAS:6967-29-9 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Ethenyldiethoxymethylsilane CAS:5507-44-8 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.Advanced intermediate suppliers not only have strong bargaining power for junior suppliers, but more importantly, because they undertake the production of advanced intermediates with high technical content and maintain closer ties with multinational companies, raw materials Price fluctuations have little effect on it.

Related Products
Product Name
4-chloro-N-methylpyridine-2-carboxamide,hydrochloride View Details
L-Glutamic acid dimethyl ester hydrochloride View Details
Trimethyloxonium Tetrafluoroborate View Details
1-Chlorohexadecane manufacturer [2-acetamido-2-(acetyloxymethyl)-4-phenylbutyl] acetate manufacturer 2,4-Dibromotoluene manufacturer 3-(Methylamino)piperidine Dihydrochloride manufacturer Poly[trifluoropropyl(methyl)siloxane] manufacturer